CClinicalTrials.gg
CompletedNCT01770314Updated May 19, 2014Results posted

Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.

A Phase 2 interventional study of Experimental in Medication Adherence, sponsored by Inflexxion, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-19.

Sponsored by Inflexxion, Inc. · Phase 2, Interventional, and Prevention

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this project is to test whether an online pain medication intervention is a feasible and effective way to increase opioid pain medication safety.

Read the detailed description

The goal of the study is to test the efficacy of the pain medication safety intervention for increasing safe management of prescription medication opioids. The study will use a randomized, controlled design that compares the intervention (painACTION medication safety lessons) to a waitlist control condition.

The hypotheses related to efficacy are that, as compared to the control group, people in the experimental group will demonstrate:

  1. Increased self-efficacy for how to safely manage medications (primary outcome)
  2. Increased behaviors associated with safely managing medication (secondary outcome)

Participants:

Investigators will recruit the first 148 respondents who meet the inclusion criteria and consent to be in the study.

Experimental Group. Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.

Control Group. The control group is a waitlist control. Participants will be given access to painACTION after the intervention period and follow up assessments are completed.

Randomization: Participants will be randomized by gender and age.

Procedure: Participants will be recruited with the help of the participating clinic. Staff members will let people know about the study by giving out informational fliers. The flier will direct people who are interested in participating in the study to an online screener. Those who screen in will automatically be lead to a consent form. Participants randomized to use painACTION will be sent the link to the online program and provided with a code that will serve as a Personal Identification Number (PIN) to access the program and return for subsequent sessions. The codes will also allow research staff to track program activity. The numbers are generated as participants agree to participate in the study and will begin with 0001 and continue to 0140 as the investigators add participants. The Research Coordinator will only provide assistance with the technical aspects of navigating the program. All assessments will be administered online. The battery will take no more than thirty minutes to complete. Several studies have determined that online assessments have many advantages over other modes of data collection (Webb et al., 1999; Yun, 2000). Online administration allows: (1) automation of the data collection process; (2) standardization of administration; (3) the use of personalized e-mail invitations at the precise assessment time points; (4) opportunities for participants to complete questionnaires on their own time and in the setting most comfortable to them; and (5) greater protection of confidentiality and conservation of resources because no written record exists. In addition, a number of studies have demonstrated that participants prefer computer-assisted self-interviews to traditional methods of data collection, and are more honest with computers (Johnston \& Walton, 1995, Paperny et al., 2000). The increase in precision translates to greater power to detect real effect differences and higher confidence in the validity of the data. Information will not be saved if the browser is closed and the questionnaire has not been completed and submitted.

Assessments: Data will be collected from participants at baseline, immediately after the intervention, and one month post intervention.

02

Conditions studied

  • Medication Adherence

Keywords

  • Opioid Pain Medication
  • Medication Safety
  • Correct storage
  • Correct disposal
  • Correct Use
03

In context

Lead sponsor

Inflexxion, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Be willing and able to provide consent
  • Have the ability to read and write English
  • Diagnosis of non-cancer chronic pain
  • Prescribed opioids and taking consistently for 3 months.
  • Over 18 years old

Exclusion criteria

Exclusion Criteria:

  • Previously visited painACTION
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Experimental

    Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.

    Behavioral: Experimental

  • No intervention
    Control

    The control group is a waitlist control. Participants will be given access to painACTION after the intervention period and follow up assessments are completed.

Interventions

  • BehavioralExperimental

    Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.

    Also known as: painACTION website

06

What researchers measure

Primary outcomes

  1. Self-efficacy - 8 Item Measure Taps Into Key Concepts Associated With Confidence for Managing Opioid Medications

    Responses are measured on a 4-point Likert scale (1= "Not at all confident" and 4= "Extremely confident"). The total Score range:8=least confident, 32=most confident. How confident do you feel in your ability to do each of the following activities, today? 1. I can recognize side effects that are related to my opioid medicine. 2. I can avoid giving my opioid medicine to someone else. Etc.. 1 - Not at all confident 2 - Somewhat confident 3 - Very confident 4 - Extremely confident Items have been generated from literature. Content validity: assessed by asking two experts if items are important and relevant. Internal consistency of the items in the pilot measure will be assessed (Cronbach's alpha). Test-retest reliability will be explored by asking 50 participants in the control group to retake the pilot measure within 3-5 days of having taken the measure as part of the pretest.

    Time frame: Baseline - Day 1, Posttest - Day 16 (intervention took 15 days), One month Followup - at 1 month post-intervention

Secondary outcomes

  1. Satisfaction With the Program

    We tested and analyzed participants' satisfaction with the program by asking the question: "Overall, how satisfied were you with the lessons." They answered on a 4 point Likert scale: 1=Not at all satisfied, 2=Somewhat Satisfied, 3=Satisfied, 4 = Very satisfied. Higher values indicate higher satisfaction.

    Time frame: One-month followup assessment

07

Results

Posted May 19, 2014

Participant flow

Participants were recruited via an online advertisement as well as through posters

Participant flow — Overall Study
MilestoneControlExperimental
Started8690
Contributed data to baseline6872
Contributed data to post-test6567
Contributed data to one-month follow-up6166
Completed8690
Not completed00

Outcome measures

PrimarySelf-efficacy - 8 Item Measure Taps Into Key Concepts Associated With Confidence for Managing Opioid Medications

Responses are measured on a 4-point Likert scale (1= "Not at all confident" and 4= "Extremely confident"). The total Score range:8=least confident, 32=most confident. How confident do you feel in your ability to do each of the following activities, today? 1. I can recognize side effects that are related to my opioid medicine. 2. I can avoid giving my opioid medicine to someone else. Etc.. 1 - Not at all confident 2 - Somewhat confident 3 - Very confident 4 - Extremely confident Items have been generated from literature. Content validity: assessed by asking two experts if items are important and relevant. Internal consistency of the items in the pilot measure will be assessed (Cronbach's alpha). Test-retest reliability will be explored by asking 50 participants in the control group to retake the pilot measure within 3-5 days of having taken the measure as part of the pretest.

Time frame:
Baseline - Day 1, Posttest - Day 16 (intervention took 15 days), One month Followup - at 1 month post-intervention
Reported as:
Least squares mean · units on a scale
Self-efficacy - 8 Item Measure Taps Into Key Concepts Associated With Confidence for Managing Opioid Medications
units on a scaleExperimentalControl
Baseline Least Square Means (n=72, 68)28.1081 ± 0.541227.0563 ± 0.5525
Post-test Least Square Means (n=67,65)29.7143 ± 0.422228.3224 ± 0.4254
One-month follow-up Least Square Means (n=66,61)30.2064 ± 0.424628.5664 ± 0.4352
SecondarySatisfaction With the Program

We tested and analyzed participants' satisfaction with the program by asking the question: "Overall, how satisfied were you with the lessons." They answered on a 4 point Likert scale: 1=Not at all satisfied, 2=Somewhat Satisfied, 3=Satisfied, 4 = Very satisfied. Higher values indicate higher satisfaction.

Time frame:
One-month followup assessment
Reported as:
Mean · units on a scale
Satisfaction With the Program
units on a scaleExperimentalControl
Satisfaction With the Program3.6470588 ± 0.6063391—

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental—0/90 (0%)0/90 (0%)
Control—0/86 (0%)0/86 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ExperimentalControlTotal
<=18 years000
Between 18 and 65 years8385168
>=65 years718
Age, Continuous
Age, Continuous(years)ExperimentalControlTotal
Mean47 ± 11.845 ± 10.546 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)ExperimentalControlTotal
Female5755112
Male333164
Region of Enrollment
Region of Enrollment(participants)ExperimentalControlTotal
United States9086176
08

Study locations

1 site
  • Inflexxion Inc
    Newton, Massachusetts 02464, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01770314
Lead sponsor
Inflexxion, Inc.
Responsible party
Sponsor
First posted
Jan 17, 2013
Start date
Sep 2012
Primary completion
Apr 2013
Completion
Sep 2013
Results posted
May 19, 2014
Last update
May 19, 2014

Study contacts

Elizabeth Donovan, Ph. D.
principal investigator · Inflexxion, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion